Plasma levels of soluble receptor for advanced glycation end products in Alzheimer's disease

International Journal of Neuroscience

Volumn 127, Issue 5, 2017, Pages 454-458

  Xu, Xiao Yan ^a   Deng, Chang Qing ^a   Wang, Jian ^a   Deng, Xiao Juan ^a   Xiao, Qian ^a   Li, Yuan ^b   He, Qi ^a   Fan, Wen Hui ^a   Quan, Feng Ying ^a   Zhu, Yao Ping ^a   Cheng, Ping ^a   Chen, Guo Jun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b SHANDONG MENTAL HEALTH CENTER   (China)

Author keywords

Alzheimer's disease; dementia; diagnose; ELISA; plasma level; sRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEMENTIA; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED DEPRESSION AND DEMENTIA; MULTIINFARCT DEMENTIA; PARALYTIC DEMENTIA; PARKINSON DISEASE DEMENTIA; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETER; VERY ELDERLY; ANALYSIS OF VARIANCE; BLOOD; DAILY LIFE ACTIVITY; MENTAL HEALTH; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; DEMENTIA, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; REGRESSION ANALYSIS; ROC CURVE;

EID: 84975230355     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.1080/00207454.2016.1193861     Document Type: Article

References (22)

1. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011;7(3):137–52. doi:10.1038/nrneurol.2011.2.
2. Stella F, Radanovic M, Balthazar ML, et al. Neuropsychiatric symptoms in the prodromal stages of dementia. Curr Opin Psychiatry 2014;27(3):230–5. doi:10.1097/YCO.0000000000000050.
3. Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia:a systematic review and meta-analysis. Alzheimers Dement 2013;9(1):63–75. doi:10.1016/j.jalz.2012.11.007.
4. Nakamura K, Yamagishi S, Adachi H, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 2007;23(5):368–71. doi:10.1002/dmrr.690.
5. Poulsen MW, Hedegaard RV, Andersen JM, et al. Advanced glycation endproducts in food and their effects on health. Food Chem Toxicol 2013;60:10–37. doi:10.1016/j.fct.2013.06.052.
6. Zhang L, Bukulin M, Kojro E, et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 2008;283(51):35507–16. doi:10.1074/jbc.M806948200.
7. Ott C, Jacobs K, Haucke E, et al. Role of advanced glycation end products in cellular signaling. Redox Biol 2014;2:411–29. doi:10.1016/j.redox.2013.12.016.
8. Shimizu F, Sano Y, Tominaga O, et al. Advanced glycation end-products disrupt the blood–brain barrier by stimulating the release of transforming growth factor-beta by pericytes and vascular endothelial growth factor and matrix metalloproteinase-2 by endothelial cells in vitro. Neurobiol Aging 2013;34(7):1902–12. doi:10.1016/j.neurobiolaging.2013.01.012.
9. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996;382(6593):685–91. doi:10.1038/382685a0.
10. Gaens KH, Ferreira I, van der Kallen CJ, et al. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab 2009;94(12):5174–80. doi:10.1210/jc.2009-1067.
11. Zhang L, Postina R, Wang Y. Ectodomain shedding of the receptor for advanced glycation end products:a novel therapeutic target for Alzheimer's disease. Cell Mol Life Sci 2009;66(24):3923–35. doi:10.1007/s00018-009-0121-4.
12. Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008;22(10):3716–27. doi:10.1096/fj.08-109033.
13. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood–brain barrier and accumulation in brain. Nat Med 2003;9(7):907–13. doi:10.1038/nm890.
14. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood–brain barrier. Stroke 2004;35(11 Suppl 1):2628–31. doi:10.1161/01.STR.0000143452.85382.d1.
15. Yan SD, Bierhaus A, Nawroth PP, et al. RAGE and Alzheimer's disease:a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis 2009;16(4):833–43. doi:10.3233/JAD-2009-1030.
16. Hofmann MA, Drury S, Hudson BI, et al. RAGE and arthritis:the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002;3(3):123–35. doi:10.1038/sj.gene.6363861.
17. Emanuele E, D'Angelo A, Tomaino C, et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005;62(11):1734–6. doi:10.1001/archneur.62.11.1734.
18. Stamps JJ, Bartoshuk LM, Heilman KM. A brief olfactory test for Alzheimer's disease. J Neurol Sci 2013;333(1–2):19–24. doi:10.1016/j.jns.2013.06.033.
19. Liang F, Jia J, Wang S, et al. Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer's disease. J Clin Neurosci 2013;20(3):357–61. doi:10.1016/j.jocn.2012.06.005.
20. Liang F, Jia J, Wang S, et al. Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer's disease. J Clin Neurosci 2013;20(3):357–61. doi:10.1016/j.jocn.2012.06.005.
21. Perrone L, Grant WB. Observational and ecological studies of dietary advanced glycation end products in national diets and Alzheimer's disease incidence and prevalence. J Alzheimers Dis 2015;45(3):965–79. doi:10.3233/JAD-140720.
22. Cai W, Uribarri J, Zhu L, et al. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci U S A 2014;111(13):4940–5. doi:10.1073/pnas.1316013111.